Skip to main content

My account

Boston Scientific accounts are for healthcare professionals only.

Create an account to access online training and education on EDUCARE, manage your customer profile, and connect with customer support and service teams.

My Boston Scientific account

Access your online applications and manage your customer profile.

Manage my Boston Scientific account

Quick Links

Contact a representative
Online education and training
Order products online
Reimbursement resources
Return a product
Customer support

Call customer care

1 (888) 272-1001

Internal view of patient's torso demonstrating targeted accuracy of TheraSphere Y-90 Glass Microspheres in liver.

TheraSphere™ Y-90 Glass Microspheres

TARGET Study

TARGET study overview

A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study.

The TARGET study confirms TheraSphere treatment for HCC as safe and effective in select patient populations. Predictable clinical outcomes from this real-world study span a broad group across 8 countries.

Download TARGET study analysis

Filename
TARGET_Data_Sheet.pdf
Size
633 KB
Format
application/pdf
Download TARGET study analysis
See full manuscript
Filename
TARGET_study_presentation.pptx
Size
2 MB
Format
application/vnd.openxmlformats-officedocument.presentationml.presentation
Download TARGET PowerPoint presentation

Lam, M., Garin, E., Maccauro, M. et al. A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging (2022). https://doi.org/10.1007/s00259-022-05774-0.

Study objective

Establish the relationships between:

  • Normal tissue adsorbed dose (NTAD) and occurrence of grade 3 or higher hyperbilirubinemia
  • Tumor absorbed dose (TAD) and Objective Response Rate (ORR)
  • TAD and Overall Survival (OS)

Study design

Key patient characteristics

  • Mainly Intermediate and Advanced HCC: 32.5% BCLC B and 54.5% BCLC C
  • 7cm median target lesion
  • 33% PVT*

Dosimetry approach

  • Investigator review of patient chart and dosimetry calculation
  • Retrospective dosimetry evaluation with multi-compartment approach using Simplicit90Y™ personalized dosimetry software to determine TAD and NTAD

*TheraSphere not indicated for patients with PVT.

Results

Graph showing Median OS: 20.3 months (95% CI: 16.7-26.4 months), measuring survival probability over time (in months).

70.8% ORR*

for the target lesion (mRECIST)

61.7% OR**

for all lesions (mRECIST)

20.3 months

median overall survival

*95% CI 64.3, 76.6
**95% CI 55.0, 68.0

Tumor absorbed dose was predictive of response¹ ²

Graph showing partial response % and complete response %, comparing <200, >=200 to <300, Tumor Absorbed Does (GY), and >+300.
  1. Total perfused tumor absorbed dose (CT/MRI workflow) and best response (61.7%) according to mRECIST.
  2. Non-responders (defined as stable disease, progressive disease, or non-evaluable) are not represented in the graph.

Responders had a

17% higher

mean tumor absorbed dose (225.5 Gy*) compared with non-responders (188.3 Gy**)

*95% CI 201.0 - 253.0 Gy
**95% CI 164.6 - 215.3 Gy; p = 0.046

Tumor absorbed dose was predictive of overall survival

Kaplan-Meier overall survival curves

Total perfused tumor absorbed dose by subgroups

Graph showing overall survival rate (%) over time (in months).

Median overall survival

>300 Gy - 36.7 months
(95% CI: 20.2 - 43.9 months)

>200 - <300 Gy - 25.1 months
(95% CI: 14.5 - 32.9 months)

<200 Gy - 16.1 months
(95% CI: 11.3 - 19.4 months)

Low rate of ≥ grade 3 hyperbilirubinemia confirms safety of TARGET study

Graph showing Probability of >= Grade 3 Hyperbilirubinemia in the Absence of Disease Progression over Absorbed Dose (Gy).

Only 4.8% of patients (10/209) experienced ≥ Grade 3 hyperbilirubinemia in the absence of disease progression.

Regarding the low rate of event, no correlation could be established with the normal tissue absorbed dose (p=0.6 for NTAD).

Table on patient characteristics, parameter, and treated population (N-209) N (%); parameters are Median age (range), years, Gender, male, ECOG Status, BCLC Status, Child-Pugh Status, Unilobar or Bilobar Disease.
Table on patient characteristics, parameter, and treated population (N-209) N (%); parameters are With PVT, Location of Target Lesion, Target Lesion Longest Diameter (RECIST 1.1), Total Number of Lesions (target and non-target).

Study takeaways

Dose matters

Deliver the highest dose to the tumor that is safely possible to maximize patient response and improve survival

 

Predictability

Predictable results across 8 countries using multi-compartmental dosimetry using Simplicit90Y personalized dosimetry software

 

Consistency

Like the Legacy study and Dosisphere-01 trial results, the Target study reinforces the association between higher tumor absorbed dose and clinical outcomes

 

Double desktop monitor showing Simplicit90Y personalized dosimetry software for TheraSphere Y-90 Glass Microspheres.

Simplicit90Y™ personalized dosimetry software

Simplicit90Y is the only Y-90 personalized dosimetry software with FDA 510K  clearance, designed specifically for TheraSphere™ Y-90 Glass Microspheres.  Simplicit90Y was developed to accelerate dosimetry planning and improve your Y-90 Selective Internal Radiation Therapy (SIRT) workflow.

Request a Simplicit90Y demo

TheraSphere is a registered trademark of Theragenics Corporation used under license by Boston Scientific Medical Device Limited, a wholly owned indirect subsidiary of Boston Scientific Corporation.